Melanoma Warning Signs: ABCDE Rules Explained

Research-informed explainer — last updated April 12, 2026

The ABCDE rule is a checklist — developed by NYU dermatologists and validated over four decades of research — that gives patients and physicians a systematic way to flag moles or spots that may be melanoma. Knowing what the letters stand for and what to actually look for can be the difference between catching a melanoma when it's thin and curable versus when it has already grown deeper.

This explainer covers what melanoma is, how to recognize warning signs using the ABCDE framework, how it's diagnosed, and what treatment looks like at different stages. It draws on published research from dermatologists at NYU, UCSF, and Harvard, including the original researchers who developed and refined the ABCDE mnemonic.

What is melanoma?

Melanoma is a cancer that starts in melanocytes — the cells that produce melanin, the pigment responsible for skin color. It most often appears on the skin as a new or changing mole or dark spot, though it can occasionally develop on mucous membranes, inside the eye, or in other locations.

What makes melanoma different from other skin cancers like basal cell carcinoma is its tendency to spread. If a melanoma grows deep enough into the skin, it can reach blood vessels and lymphatics and travel to lymph nodes or internal organs. That potential for metastasis is why early detection is so much more consequential for melanoma than for most other skin conditions.

Melanoma rates in the United States increased substantially through the late 20th century. An epidemiological study tracking US melanoma incidence found rates were rising as Americans approached the 21st century, driven in part by changing sun exposure patterns and increased detection [3]. Today, melanoma accounts for a small fraction of skin cancer cases by number but causes the overwhelming majority of skin cancer deaths.

Signs and symptoms

Most melanomas are found on the skin where they can be seen — which is part of what makes the ABCDE tool so useful. Not every atypical mole is melanoma, but the features listed below identify lesions worth evaluating.

The ABCDE rule

The ABCDE mnemonic was developed at NYU in the 1980s specifically to teach both patients and physicians what to look for during self-examination and clinical skin checks [1]. A follow-up review published in CA: A Cancer Journal for Clinicians traced how the framework evolved over its first 25 years, with the addition of the "E" criterion and updates incorporating dermoscopy and other diagnostic tools [2].

A — Asymmetry: Draw an imaginary line through the middle of the lesion. If one half doesn't match the other, that's asymmetry. Benign moles are usually symmetrical.

B — Border: The edge of a suspicious lesion is often irregular, ragged, notched, or blurred rather than smoothly defined. Melanoma borders are typically uneven.

C — Color: A single mole should be a uniform shade of brown. Concerning lesions often contain multiple colors — various shades of brown or black, with areas of red, white, or blue-black.

D — Diameter: Melanomas are often larger than 6mm (about the size of a pencil eraser), though early melanomas can be smaller. Any mole that's growing should be evaluated regardless of current size.

E — Evolving: Any lesion that changes over weeks or months — in size, shape, color, or texture, or that starts to itch, bleed, or crust — needs professional evaluation. This is the criterion that catches lesions that don't fit A through D but are still growing.

What isn't covered by ABCDE

The ABCDE rule is designed for pigmented (colored) lesions, but a small percentage of melanomas are amelanotic — they contain little to no pigment and may appear pink, red, or skin-colored. These are harder to catch with self-examination. Research on the early detection of melanoma found that the combination of physician skin exams and patient self-examination substantially reduces mortality, in part because professional exams catch the lesions that patients miss [1][5].

How melanoma is diagnosed

Skin biopsy is the definitive diagnostic step. When a dermatologist identifies a lesion that meets ABCDE criteria or otherwise looks suspicious, the lesion (or a sample of it) is removed and examined by a pathologist. The pathology report establishes whether the lesion is melanoma and, if so, its Breslow thickness — how deep the tumor has grown into the skin. Breslow thickness is the single most important prognostic factor for melanoma.

Dermoscopy — using a handheld magnifying instrument that polarizes light to see below the skin surface — significantly improves a clinician's ability to distinguish melanoma from benign lesions compared to the naked eye alone. The technology became standard in dermatology over the 1990s and beyond, as documented in the evolution of the ABCDE framework [2].

For thicker melanomas, sentinel lymph node biopsy is recommended to check whether cancer has reached the nearest lymph nodes. The AAD's melanoma management guidelines establish the criteria for when lymph node evaluation is appropriate, based on Breslow thickness and other pathology features [8].

Treatment options

Melanoma treatment depends heavily on stage at diagnosis.

Early-stage (localized) melanoma

Surgery is the primary treatment for localized melanoma. The standard approach is wide local excision — removing the tumor with a defined margin of normal tissue around it. The required margin depends on Breslow thickness: thin melanomas require narrower margins than thicker ones, as outlined in the AAD guidelines [8].

When the melanoma is thin and has been completely excised, surgery alone is often curative. Five-year survival rates for localized melanoma caught early are close to 98%.

Intermediate-stage (node involvement)

For melanomas with lymph node involvement or high-risk features, surgery is followed by adjuvant therapy to reduce recurrence risk. Immune checkpoint inhibitors — drugs that release brakes on the immune system's ability to attack cancer cells — have become standard adjuvant treatment for stage III melanoma after surgery.

Advanced (metastatic) melanoma

The treatment picture for metastatic melanoma changed fundamentally in the 2010s. Many melanomas carry a BRAF V600E mutation — research from Harvard's Melanoma and Pigmented Lesion Center found that targeted BRAF inhibitors enhance T-cell recognition of melanoma cells, providing the scientific basis for combining targeted therapy with immunotherapy [9].

Two main treatment approaches are now used for metastatic disease:

• Targeted therapy: BRAF and MEK inhibitors for tumors with BRAF V600E mutations, producing rapid responses in a high proportion of patients
• Immunotherapy: Anti-PD-1 checkpoint inhibitors (pembrolizumab, nivolumab) and anti-CTLA-4 drugs have produced durable long-term responses in a subset of patients

Mohs surgery

Mohs micrographic surgery — which maps tumor margins layer by layer under the microscope — is the appropriate approach for melanoma in certain locations (face, scalp, hands, feet) where tissue sparing matters. The AAD's Mohs surgery appropriate-use criteria cover melanoma-in-situ and lentigo maligna in specific anatomical areas [6].

What specialists are discovering

The ABCDE rule remains clinically useful, but detection technology has moved beyond it. Artificial intelligence tools trained on dermoscopic images have been shown to match or exceed dermatologist performance in distinguishing melanoma from benign lesions in controlled studies. Research on UV exposure and skin cancer has helped clarify which exposure patterns are most dangerous — both chronic cumulative UV and intermittent intense UV (sunburns) contribute to melanoma risk, by different mechanisms [4].

On the treatment side, the molecular understanding of melanoma continues to deepen. Researchers at Harvard and other centers are working to understand why some patients respond durably to checkpoint immunotherapy while others do not, and how to sequence targeted and immune therapies for the best outcomes.

Questions to ask your doctor

• Can you look at my existing moles and tell me which ones, if any, concern you?
• How often should I have a full-body skin exam given my skin type, history, and sun exposure?
• If a mole is changing but doesn't fully meet ABCDE criteria, should it still be biopsied?
• If a biopsy confirms melanoma, what does Breslow thickness mean for my prognosis?
• Do I need a sentinel lymph node biopsy, and what would a positive result mean for next steps?
• What is my melanoma's BRAF mutation status, and how does that affect treatment options?

The bottom line

Melanoma warning signs exist because early removal changes outcomes dramatically. The ABCDE rule — Asymmetry, Border, Color, Diameter, Evolving — was developed by dermatology researchers specifically to make detection systematic and teachable, and it has held up well over four decades [1][2]. The most important letter may be E: any mole that's changing over time deserves professional evaluation, even if it doesn't fit the other criteria perfectly.

Regular skin self-exams combined with annual dermatologist visits are the best current tools for catching melanoma early. If you notice any spot that looks unusual or has recently changed, don't wait.